Document:

Third Amended and Restated Investor Rights Agreement

 Exhibit 4.3 
 JAZZ PHARMACEUTICALS, INC. 
 THIRD AMENDED AND
RESTATED 
 INVESTOR RIGHTS AGREEMENT 
 THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is made effective as of the Effective Date (as defined below), by and among Jazz Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), and the holders of Common Stock, Preferred Stock and/or warrants to purchase the Series BB Preferred Stock of the Company listed on Exhibit A hereto (collectively, the
“Investors”). 
 RECITALS 
 WHEREAS, the Company and the Investors are parties to that certain Second Amended and Restated Investor Rights Agreement, dated as of June 24, 2005 (the “Prior
Agreement”); 
 WHEREAS, the Company and the Investors who have executed this Agreement (for and on behalf
of all Investors) wish to amend and restate the Prior Agreement in its entirety as set forth below; and 
 WHEREAS,
Investors who are holders of at least 60% of the Registrable Securities held by all Investors, together with Managers holding a majority of the Registrable Securities held by all Managers and the Company, have the right, pursuant to
Section 19.5 of the Prior Agreement, to amend and restate the Prior Agreement in its entirety as set forth below. 
 NOW, THEREFORE, in consideration of the mutual agreements, covenants and considerations contained herein, the Company and the Investors who have executed this Agreement (for and on behalf of all
Investors) hereby agree to amend and restate the Prior Agreement in its entirety as follows: 
 1. Certain Definitions. As used
in this Agreement, the following terms shall have the following respective meanings: 
 1.1 “Affiliate” shall mean,
with respect to any Person, a Person directly or indirectly controlling, controlled by, or under common control with, such Person; provided, however, that, except for purposes of Section 11.2, no Series BB Holder shall be
considered an Affiliate of any other Person except to the extent, and only to the extent, that such Series BB Holder holds Convertible Securities (or shares of Common Stock issued upon conversion thereof) other than Series BB Preferred Stock (or
shares of Common Stock issued upon conversion thereof). 
 1.2 “Commission” shall mean the Securities and Exchange
Commission or any other federal agency at the time administering the Securities Act. 
 1.3 “Control” shall have the
meaning given such term under Rule 405 of the Securities Act. 

 1.4 “Convertible Securities” shall mean the shares of the Company’s Series A
Preferred Stock, Series B Preferred Stock, Series B Prime Preferred Stock (“Series B/P Preferred Stock”) and Series BB Preferred Stock held from time to time by the Investors and their permitted assigns. 
 1.5 “Effective Date” shall mean the date of the closing of the Initial Public Offering. 
 1.6 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 1.7 “Form S-1” shall mean Form S-1 issued by the Commission or any comparable or successor form or forms then in effect.

 1.8 “Form S-3” shall mean Form S-3 issued by the Commission or any comparable or successor form or forms then in
effect. 
 1.9 “Group” means two or more Persons acting together as a partnership, limited partnership, syndicate or
other group for the purpose of acquiring, holding or disposing of or voting securities of the Company. 
 1.10
“Holder” shall mean any holder of outstanding Registrable Securities which have not been sold to the public, but only if such holder is one of the Investors or an assignee or transferee of registration rights as permitted by
Section 11. 
 1.11 “Initial B/P Holder” shall mean a Person that holds any shares of Series B/P Preferred Stock
as of the date the first share of Series B/P Preferred Stock is issued. 
 1.12 “Initial Public Offering” shall mean
the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act 
 1.13
“KKR” shall mean Kohlberg Kravis Roberts & Co. L.P. and its Affiliates. 
 1.14
“Managers” shall mean Samuel R. Saks, Bruce C. Cozadd, Robert M. Myers, Matthew K. Fust, Carol A. Gamble and Janne L.T. Wissel. 
 1.15 “Material Adverse Event” shall mean any change, event or effect that is materially adverse to the general affairs, business, operations, assets, prospects, condition (financial or
otherwise) or results of operations of the Company and its subsidiaries taken as a whole. 
 1.16 “Person” means an
individual, partnership, corporation, limited liability company, limited partnership, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature. 
 1.17 The term “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred Stock, Series B/P Preferred Stock and
Series BB Preferred Stock of the Company. 
  

 2 

 1.18 The terms “Register”, “Registered”, and
“Registration” refer to a registration effected by preparing and filing a registration statement on Form S-1, S-2 or S-3 in compliance with the Securities Act (“Registration Statement”), and the
declaration or ordering of the effectiveness of such Registration Statement. 
 1.19 “Registrable Securities” shall
mean (i) any Common Stock now owned or hereafter acquired by a Manager, (ii) the Common Stock issued or issuable upon conversion of the Convertible Securities, and (iii) any Common Stock issued (or issuable upon conversion or exercise
of any warrant, right or other security which is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or in replacement of, such securities identified in
clauses (i) and (ii) and this clause (iii), provided, however, that no shares of Common Stock shall be deemed Registrable Securities for purposes of this Agreement to the extent that such shares of Common Stock (A) have
been sold to the public through a Registration Statement or pursuant to Rule 144; (B) have been sold, transferred or otherwise disposed by a person in a transaction in which its rights under this Agreement were not assigned; (C) are held
by a Holder or Investors whose rights to cause the Company to register securities pursuant to this Agreement have terminated in accordance with Section 6 of this Agreement. 
 1.20 “Registration Expenses” shall mean (a) all expenses incurred by the Company or its subsidiaries in complying with
Sections 3 or 4 of this Agreement, including, without limitation, all federal and state registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and expenses, and the expense
of any regular or special audits incident to or required by any such registration, and (b) the expenses of one special counsel for all Holders (if different from counsel to the Company) up to $45,000 and one special counsel for all Managers (if
different from counsel to the Company) up to $45,000. 
 1.21 “Securities Act” shall mean the Securities Act of 1933,
as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 1.22 “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement, and all fees and disbursements
of counsel to the Holders and the Managers that are not included in Registration Expenses. 
 1.23 “Series BB Holder”
means a holder of warrants issued under the Stock Purchase Agreement, dated January 27, 2004 between the Company and certain Investors (as the same may be amended from time to time in accordance with the terms thereof, the “Purchase
Agreement”) to purchase shares of the Company’s Series BB Preferred Stock (“Series BB Warrants”) or Series BB Preferred Stock (or shares of Common Stock issued upon conversion thereof). 
 1.24 “Special Registration Statement” shall mean (i) any registration statement relating to any employee benefit plan;
(ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statement related to the 

  

 3 

 
issuance or resale of securities issued in such a transaction; (iii) any registration statement related to stock issued upon conversion of debt
securities; or (iv) any WKSI Shelf Registration Statement that the Company’s Board of Directors shall, in its sole discretion, designate as a “Special Registration Statement” for purposes of this Agreement. 
 1.25 “WKSI Shelf Registration Statement” shall mean a registration statement on Form S-3 under the Securities Act (or any
successor form to Form S-3) which registration statement shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act (or any successor or similar rule under the Securities Act adopted by the Commission).

 2. Confidentiality. Each Investor agrees that it will keep confidential and will not use (except in connection with the
evaluation or monitoring of its investment or its representative’s service on the Board of Directors of the Company), disclose or divulge for a period of three years after receipt of any information regarding the Company and its business which
such Investor obtained from the Company pursuant to Section 2 of the Prior Agreement, and which the Company has marked or otherwise specifically identified to the Investor as being confidential either orally or in writing, unless such
information is known, or until such information becomes known, to the public through no fault of such Investor or its agents, or unless the Board of Directors, Chief Executive Officer, President or General Counsel of the Company gives his or her
written consent to the Investor’s release of such information, except that no such written consent shall be required (and the Investor shall be free to release such information) if such information is to be provided to the Investor’s
counsel or accountant, or to an officer, director, general partner, limited partner, stockholder, investment counselor or advisor of an Investor or such Investor’s Affiliate, or employee of an Investor or such Investor’s Affiliate with a
need to know such information; provided that any such counsel, accountant, officer, director, general partner, limited partner, stockholder, investment counselor or advisor, or employee is subject to confidentiality obligations no less restrictive
in any material respects than the provisions of this Section 2. Notwithstanding the foregoing, this Section 2 shall not apply (a) to information which an Investor learns from a third party with the right to make such disclosure,
provided such Investor complies with the restrictions imposed by the third party, (b) to information which is in an Investor’s possession prior to the time of disclosure by the Company and not acquired by such Investor under a
confidentiality obligation, (c) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by law or a governmental regulatory authority,
(d) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by court order, (e) to general and summary information disclosed to an
Investor’s or such Investor’s Affiliates’ general partners, limited partners, members, and/or stockholders in such Investor’s or such Affiliates’ periodic reporting to such parties or to an Investor’s or such
Investor’s Affiliates’ prospective investors in such Investor’s or such Affiliates’ marketing activities, in a manner consistent with the custom and practice of the private venture capital and/or private equity industries,
provided that such Investor or such Affiliate advise such parties that the information disclosed is confidential, and provided further that the information disclosed does not include any proprietary information of the Company, and (f) to an
Investor’s disclosure of the fact that such Investor has made an investment in the Company, the amount and general nature thereof, the identity of such Investor’s co-investors in the Company if previously disclosed by the Company or such
co-investor, and to such Investor’s disclosure of the general business and goals of the Company. 
  

 4 

 3. Demand Registrations. 
 3.1 Requests for Registration on Form Other Than Form S-3. 
 (a) Subject to the terms of this Agreement, in the event that the Company shall receive from a Holder or Holders (not including any Managers) of at least 40% of the Registrable Securities (or a lesser percentage of
such shares if the anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) at any time after six months after the effective date of the Registration Statement with respect to the Initial
Public Offering, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such shares if the anticipated aggregate price to the
public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as
practicable, and in any event, within 90 days from receipt of notice from the Holders requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such request, together with any Registrable
Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a registrant qualified to use Form S-3, the Company shall not be obligated to take any action
to effect any such registration pursuant to this Section 3.1(a) after the Company has effected one such Registration pursuant to this Section 3.1(a) and such Registration has been declared effective; provided, however, that
the demand registration under this Section 3.1(a) shall be in addition to the demand registration provided for under Section 3.1(b). 
 (b) Subject to the terms of this Agreement, in the event that the Company shall receive from a Holder who originally committed to purchase (and did not default in any purchase) at least 50,000,000 shares of Series B Preferred Stock and/or
Series B/P Preferred Stock (appropriately adjusted for combinations, consolidations, subdivisions, recapitalizations, stock splits and the like with respect to such shares) at any time after six months after the effective date of the Registration
Statement with respect to the Initial Public Offering, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such shares if the
anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders
and (ii) as soon as practicable, and in any event, within 90 days from receipt of notice from the Holder requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such request,
together with any Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a registrant qualified to use Form S-3, the Company shall not
be obligated to take any action to effect any such registration pursuant to this Section 3.1(b) after the Company has effected one such Registration pursuant to this Section 3.1(b) and such Registration has been declared effective;
provided, however, that the demand registration under this Section 3.1(b) shall be in addition to the demand registration provided for under Section 3.1(a). 
  

 5 

 (c) Notwithstanding anything to the contrary in Sections 3.1(a) and 3.1(b), the right of Managers to
participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 3.1(a) or 3.1(b) that exceeds X; where X equals the number of Registrable Securities held by such
Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other
than Managers) divided by the total number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by such Holders (other than Managers). This
paragraph (c) shall terminate and be of no force and effect from such time, if any, as KKR ceases to own either Convertible Securities or Registrable Securities. 
 3.2 Request for Registration on Form S-3. 
 (a) If a Holder or Holders (not including any
Managers) of at least 20% of the outstanding shares of Registrable Securities requests that the Company file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, the anticipated aggregate price to the public of
which, net of Selling Expenses, would not be less than $25,000,000, and the Company is a registrant qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as
practicable, use reasonable best efforts to effect a Registration of the Registrable Securities on such form, together with the Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after
notice from the Company; provided, however, that the Company shall not be required to effect more than two Registrations pursuant to Section 3.2 in any 12 month period. All of the provisions of Section 3.5 shall be applicable
to each Registration initiated under this Section 3.2. 
 (b) For each $40,000,000 in original issue price of Registrable Securities
purchased by a Holder (a “Principal Holder”), such Principal Holder may request that the Company file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, and provided that the anticipated
aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000 and the Company is a registrant qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all
other Holders and (ii) as soon as practicable, use reasonable best efforts to effect a Registration of the Registrable Securities on such form, together with the Registrable Securities of any Holder joining in such request as are specified in a
notice given within 20 days after notice from the Company; provided, however, that the Company shall not be required to effect more than two Registrations pursuant to Section 3.2 in any 12 month period. A Principal Holder shall
have the right to demand one Registration under this Section 3.2(b) for each $40,000,000 in original issue price of Registrable Securities purchased by such Holder. All of the provisions of Section 3.5 shall be applicable to each
Registration initiated under this Section 3.2. 
 (c) Notwithstanding anything to the contrary in Sections 3.2(a) and 3.2(b), the right
of Managers to participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 3.2(a) or 3.2(b) that exceeds X; where X equals the number of Registrable Securities
held by such Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the 

  

 6 

 
total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers)
divided by the total number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by all Holders (other than Managers). This paragraph
(c) shall terminate and be of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
 3.3 Right of Deferral. 
 (a) Notwithstanding the foregoing, the Company shall not be obligated
to file a Registration Statement pursuant to Section 3: 
 (i) if the Company, within ten days of the receipt of the request from
Holders, gives notice of its bona fide intention to effect the filing of a Registration Statement with the Commission subject to Section 4 hereof within 60 days of receipt of such request (other than to a Registration of securities in a Rule
145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing all reasonable best efforts to cause such Registration Statement to become effective; 
 (ii) within 120 days immediately following the effective date of any Registration Statement pertaining to the securities of the Company (other than
a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan); or 
 (b) Notwithstanding the
foregoing, the Company shall not be obligated to file a Registration Statement pursuant to Section 3 if the Company shall furnish to the requesting Holders a certificate signed by the Chief Executive Officer of the Company stating that in the
good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a Registration Statement to be filed in the near future, then the Company’s obligation to use all reasonable best efforts to
file a Registration Statement shall be deferred for a period not to exceed 120 days from the receipt of the request to file such registration by such Holders; provided, however, that the Company shall not exercise the deferral rights
contained in these Sections 3.3(a)(i) and 3.3(b) more than once in any 12-month period. 
 3.4 Registration of Other Securities in
Demand Registration. Any Registration Statement filed pursuant to the request of the Holders under this Section 3 may, subject to the provisions of Section 3.5, include securities of the Company other than Registrable Securities.

 3.5 Underwriting in Demand Registration. 
 (a) Notice of Underwriting. If the Holders intend to distribute the Registrable Securities covered by their request made pursuant to this Section 3 by means of an underwriting, they shall so advise
the Company as a part of their request, and the Company shall include such information in the notice referred to in Sections 3.1 and 3.2. The right of any Holder to Registration pursuant to Section 3 shall be conditioned upon such Holder’s
agreement to participate in such underwriting and the inclusion of such Holder’s eligible Registrable Securities in the underwriting. 
  

 7 

 (b) Selection of Underwriter in Demand Registration. If a Registration requested pursuant
to Section 3.1 or 3.2 is to be underwritten, the Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement and related agreements with the representative
(“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being registered by the Holders and reasonably acceptable to
the Company. 
 (c) Marketing Limitation in Demand Registration. If the Underwriter’s Representative advises the Holders
in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the
Registration) require a limitation of the number of shares to be underwritten, then the number of shares of Registrable Securities that may be included in the Registration and underwriting shall be allocated among all Holders in proportion, as
nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this
Section 3.5(c) shall be included in such Registration Statement. 
 (d) Right of Withdrawal in Demand Registration. If
any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by notice to the Company, the Underwriter’s Representative and the Holders requesting Registration delivered at least
ten days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 
 4. Piggyback Registration. 
 4.1 Notice of Piggyback Registration and Inclusion of
Registrable Securities; Special Limitation for Managers. 
 (a) Subject to the terms of this Agreement, if the Company
decides to Register any of its Common Stock on a form that would be suitable for a registration of Registrable Securities, other than a Special Registration Statement, whether pursuant to a demand registration contemplated by this Agreement or
otherwise, the Company will: (i) promptly give each Holder notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under the applicable Blue Sky or other state
securities laws) and (ii) subject to Section 4.2, include in such Registration (and any related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a
notice delivered to the Company by any Holder within 20 days after delivery of such notice from the Company. 
 (b) Notwithstanding anything
to the contrary in Section 4.1(a), the right of Managers to participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 4.1 that exceeds X; where X equals
the number of Registrable Securities held by such Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the total number of shares of 

  

 8 

 
Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers) divided by the total number
of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by all Holders (other than the Managers). This paragraph (b) shall terminate and be
of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
 4.2
Underwriting in Piggyback Registration. 
 (a) Notice of Underwriting in Piggyback Registration. If the
Registration of which the Company gives notice is for a Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the notice given pursuant to Section 4.1. In such event, the right of any Holder
to Registration shall be conditioned upon such underwriting and the inclusion of such Registrable Securities in such underwriting to the extent provided in this Section 4. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company) enter into an underwriting agreement and related agreements with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection of the
underwriters for an offering pursuant to this Section 4. 
 (b) Marketing Limitation in Piggyback Registration. If the
Underwriter’s Representative advises the Holders seeking registration of Registrable Securities pursuant to this Section 4 in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock
requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the Underwriter’s
Representative (subject to the allocation priority set forth in Section 4.2(c)) may: 
 (i) in the case of the Initial Public Offering,
exclude some or all of the Registrable Securities from such registration and underwriting; and 
 (ii) in the case of any Registered public
offering subsequent to the Initial Public Offering, limit the number of shares of Registrable Securities to be included in such Registration and underwriting to not less than 30% of the securities included in such Registration. 
 (c) Allocation of Shares in Piggyback Registration. If the Underwriter’s Representative limits the number of shares to be included in
a Registration pursuant to Section 4.2(b), the number of shares to be included in such Registration shall be allocated among all Holders, in proportion, as nearly as practicable, to the respective amounts of Registrable Securities which such
Holders hold at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 4.2(c) shall be included in the Registration Statement. 
 (d) Withdrawal in Piggyback Registration. If any Holder disapproves of the terms of any such underwriting, such person may elect to
withdraw therefrom by notice to the Company and the Underwriter’s Representative delivered at least ten days prior to the effective date of the Registration Statement. Any Registrable Securities or other securities excluded or withdrawn from
such underwriting shall be withdrawn from such Registration. 
  

 9 

 5. Expenses of Registration. All Registration Expenses incurred in connection with
Registrations pursuant to Section 3.1, 3.2 and 4, shall be borne by the Company. All Registration Expenses incurred in connection with any other Registration, qualification, or compliance, shall be apportioned among the Company and the Holders
of the securities so registered on the basis of the number of shares so registered. Notwithstanding the above, the Company shall not be required to pay for any expenses of any Registration proceeding begun pursuant to Section 3 if the
Registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (which Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree
to forfeit their right to one Registration pursuant to Section 3; provided, however, that if at the time of such withdrawal, the Holders have learned of a Material Adverse Event not known to the Holders at the time of their
request, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 3. All Selling Expenses shall be borne by the holders of the securities Registered pro rata on the basis of the number
of shares Registered. 
 6. Termination of Registration Rights. The rights to cause the Company to register securities granted
under Sections 3 and 4 of this Agreement and to receive notices pursuant to Section 4 of this Agreement shall terminate, with respect to each Holder, on the earlier of (i) the twelfth anniversary of the date that the first share of Series
B Preferred Stock is sold and issued by the Company, and (ii) with respect to each Holder if such Holder is eligible to sell all of such Holder’s Registrable Securities under Rule 144 of the Securities Act (excluding Rule 144(k)
thereunder) within any three month period without volume limitations. 
 7. Registration Procedures and Obligations. Whenever
required under this Agreement to effect any Registration of securities, the Company shall, as expeditiously as reasonably possible: 
 (a)
Prepare and file with the Commission a Registration Statement with respect to such securities and use its reasonable best efforts to cause such Registration Statement to become effective, and, in the case of a Registration pursuant to Section 3
or Section 4, upon the request of the sellers of a majority of the Registrable Securities registered thereunder, keep such Registration Statement effective for up to two years. 
 (b) Furnish to each seller of Registrable Securities a copy of any information contained in the Registration Statement about such seller for the purpose
of allowing the seller to verify the information. 
 (c) Prepare and file as expeditiously as reasonably practicable with the Commission
such amendments and supplements to such Registration Statement and the prospectus used in connection with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such Registration Statement. 
  

 10 

 (d) Furnish to the sellers of Registrable Securities such numbers of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (e) Use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the sellers of Registrable Securities, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business
in any jurisdiction where it is not so qualified or to file a general consent to service of process in any such states or jurisdictions, and provided further that in the event any jurisdiction in which the securities shall be qualified imposes a
non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders. 
 (f) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement and related agreements, in
usual and customary form, with the managing underwriter of such offering. Each seller of Registrable Securities participating in such underwriting shall also enter into and perform its obligations under such an agreement and related agreements.

 (g) Promptly notify each seller of Registrable Securities covered by such Registration Statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (h) Provide a transfer agent and registrar for all securities registered pursuant to such Registration Statement and a CUSIP number for all such securities, in each case not later than the effective date of such
registration. 
 (i) Furnish, at the request of any Holder requesting Registration of Registrable Securities pursuant to this Agreement, on
the date that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such Registration, in
form and substance as is customarily given to underwriters (with an information copy provided to each Holder selling Registrable Securities) in an underwritten public offering, and (ii) a letter dated such date, from the independent certified
public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters (with an information copy provided to each
holder of Registrable Securities). 
 (j) Use all reasonable best efforts to list the securities covered by such Registration Statement with
NASDAQ or any securities exchange on which the Common Stock of the Company is then listed, or NASDAQ or such securities exchange as shall be selected by the Company. 
  

 11 

 (k) Notify each seller of Registrable Securities under such Registration Statement of (i) the
effectiveness of such Registration Statement, (ii) the filing of any post-effective amendments to such Registration Statement, or (iii) the filing of a supplement to such Registration Statement. 
 (l) Make available for inspection upon reasonable notice during the Company’s regular business hours by each seller of Registrable Securities, any
underwriter participating in any distribution pursuant to such Registration Statement, and any attorney, accountant or other agent retained by such seller or underwriter, all material financial and other records, pertinent corporate documents and
properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such Registration Statement.
Each seller of Registrable Securities agrees to use the same degree of care as such seller uses to protect its own confidential information, but in no event less than reasonable care, to keep confidential any information furnished to it by the
Company pursuant to this Subsection 7(l) for a period of 3 years (so long as such information is not in the public domain); provided, however, such seller’s obligation to keep information confidential under this Subsection 7(l)
shall not apply (a) to information which such seller learns from a third party with the right to make such disclosure, provided the seller complies with the restrictions imposed by the third party, (b) to information which is in
seller’s possession prior to the time of disclosure by the Company and not acquired by seller under a confidentiality obligation, (c) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible)
the seller is required to disclose such information by law or a governmental regulatory authority, (d) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) seller is required to disclose such
information by court order, and (e) to information disclosed to any partner, subsidiary, parent, legal counsel or advisor of such seller for the purpose of evaluating or monitoring its investment in the Company. Notwithstanding anything
herein to the contrary, any party to this Agreement (and any employee, representative, or other agent of any party to this Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the
transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure. 
 (m) Cause the senior executive officers of the Company to participate in the customary “road show” presentations that may be reasonably
requested by the Holders or the managing underwriter in any underwritten offering and otherwise to facilitate, cooperate with, and participate in each underwritten offering. 
 (n) Cooperate with each seller of Registrable Securities and each underwriter or agent, if any, participating in the disposition of such Registrable
Securities and their respective counsel in connection with any filings required to be made with the National Association of Securities Dealers, Inc. 
 8. Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under Sections 3 and 4 of this Agreement that each Holder holding
Registrable Securities included in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by such Holder(s) as the Company may reasonably request. 
  

 12 

 9. Indemnification. 
 9.1 Company’s Indemnification of Holders. To the extent permitted by law, the Company will indemnify and hold harmless
each Holder, each of its officers, directors, and constituent partners and members, legal counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification, or compliance of Registrable Securities
has been effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter against all claims, losses, damages, liabilities, or actions in respect thereof (collectively,
“Damages”) to the extent such Damages arise out of or are based upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration
Statement) incident to any such Registration, qualification, or compliance, or are based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading,
or any violation by the Company of any rule or regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification, or
compliance; and the Company will reimburse each such Holder, each such underwriter, and each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability, or action; provided, however, that the indemnity contained in this Section 9.1 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the
consent of the Company (which consent shall not unreasonably be withheld or delayed); and provided, further, that the Company will not be liable (i) in any such case to the extent that any such Damages arise out of or are based upon any untrue
statement or omission based upon written information furnished to the Company by such Holder, underwriter, or controlling person and stated to be for use in connection with the offering of securities of the Company or (ii) in the case of a sale
directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), if such untrue statement or alleged untrue
statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final or amended prospectus, and such Holder failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of the
sale of the Registrable Securities to the person asserting any such loss, claim, damage, liability or action in any case in which such delivery is required by the Securities Act. 
 9.2 Holder’s Indemnification of Company. To the extent permitted by law, each Holder will, if Registrable Securities held
by such Holder are included in the securities as to which such Registration, qualification or, compliance is being effected pursuant to this Agreement, indemnify and hold harmless the Company, each of its directors and officers, each legal counsel
and independent accountant of the Company, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning of the Securities Act, and
each other seller of Registrable Securities and each of its officers, directors, and constituent partners, and each person controlling such other seller, against all Damages arising out of or based upon any untrue 

  

 13 

 
statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular, or other document, or
any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by such Holder of any rule or regulation promulgated under the Securities
Act applicable to such Holder and relating to action or inaction required of such Holder in connection with any such Registration, qualification, or compliance, and will reimburse the Company, such other sellers of Registrable Securities, such
directors, officers, partners, persons, law and accounting firms, underwriters or control persons for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or
action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such Registration Statement, prospectus, offering circular, or other document in
reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use in connection with the offering of securities of the Company, provided, however, that the indemnity
contained in this Section 9.2 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld or delayed); and provided, further,
that each Holder’s liability under this Section 9.2 shall not exceed such Holder’s net proceeds from the offering of securities made in connection with such Registration. 
 9.3 Indemnification Procedure. Promptly after receipt by an indemnified party under this Section 9 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof and generally
summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such
claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld or delayed; provided further, however, that if either party reasonably determines that there may be a conflict
between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 9, then counsel for such party shall be entitled to conduct the
defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the
indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 9, but the omission so to notify the indemnifying party will not relieve
such party of any liability that such party may have to any indemnified party otherwise than under this Section 9. 
 9.4
Contribution. If the indemnification provided for in this Section 9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Damages referred to therein, then the
indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of
the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such Damages as well as any other relevant equitable considerations; provided, however,
that in no event shall any contribution by a 

  

 14 

 
Holder under this Section 9.4 exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The
relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 9.5 Conflicts. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 9.6 Survival of Obligations. The obligations of the Company and Holders under this Section 9 shall survive the completion of
any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 10. Limitations on
Registration Rights Granted to Other Securities. From and after the date of this Agreement, so long as at least 10,000,000 shares of the Convertible Securities (including shares of Common Stock issued upon conversion thereof and as
adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) remain issued and outstanding, the Company shall not enter into any agreement with any holder or prospective holder of any securities of
the Company providing for the granting to such holder of any Registration rights, except that, with the consent of the Holders holding at least 55% of the Registrable Securities then held by the Holders, additional persons may be added as parties to
this Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be considered a
Holder for all purposes of this Agreement and any Common Stock held by them or issued or issuable upon conversion of any securities held by them, and any Common Stock issued (or issuable upon conversion or exercise of any warrant, right or other
security which is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or in replacement of, such securities identified in this clause, excluding, however, any
securities previously sold to the public and any securities sold by a person in a transaction in which its rights under this Agreement are not assigned, shall be considered Registrable Securities. The additional parties and the additional
Registrable Securities shall be identified in an amendment to Exhibit A hereto. 
 11. Transferability. 
 11.1 Limitations on Transferability. Each Investor covenants that in no event will it dispose of any of the Convertible
Securities or Registrable Securities (other than pursuant to Rule 144 promulgated by Commission under the Securities Act (“Rule 144”) or other exemption from registration, or except in connection with an
Investor’s exercise of its Registration rights under this Agreement) unless and until (a) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances
surrounding the proposed disposition, and (b) if reasonably requested by the 

  

 15 

 
Company, the Investor shall have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and the
Company’s counsel to the effect that (x) such disposition will not require registration under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign
law has been taken. Notwithstanding the limitations set forth in the foregoing sentence, if the Investor is a partnership or limited liability company it may transfer the Convertible Securities or Registrable Securities to its constituent partners
or members or its Affiliates, or a retired partner or member of such partnership or limited liability company who retires after the date hereof, or to the estate of any such partner or member or retired partner or retired member or transfer by gift,
will, or intestate succession to any such partner’s or member’s spouse, domestic partner, lineal descendants or ancestors without the necessity of registration or opinion of counsel if the transferee agrees in writing to be subject to the
terms of the Transactional Agreements, as applicable, to the same extent if such transferee were an Investor; provided, however, that Investor hereby covenants not to effect such transfer if such transfer either would invalidate the
securities laws exemptions pursuant to which the Convertible Securities or Registrable Securities were originally offered and sold or would itself require registration and/or qualification under the Securities Act or applicable state securities
laws. Notwithstanding the foregoing, an Investor who is a Manager shall not dispose of any Convertible Securities or Registrable Securities in contravention of the Transactional Agreements (as defined herein). Each certificate evidencing the
Convertible Securities or Registrable Securities transferred as provided above shall bear the appropriate restrictive legend set forth in Section 5.1 of the Purchase Agreement, except that such certificate shall not bear such legend if the
transfer was made in compliance with Rule 144 or if the opinion of counsel referred to above is to the further effect that such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 11.2 Transfer of Rights. The right to cause the Company to Register securities granted by the Company to the Holders under
Sections 3 and 4 of this Agreement may be assigned by any Investor or its Affiliates to a transferee or assignee of any Convertible Securities or Registrable Securities not sold to the public acquiring the lesser of (a) at least 50% of the
Registrable Securities and Convertible Securities then held by such Investor or its Affiliates with respect to the first transfer by such Investor or its Affiliates to a non-Affiliate, 100% of the Registrable Securities and Convertible Securities
then held by such Investor or its Affiliates with respect to any subsequent transfer by such Investor or its Affiliates to a non-Affiliate, or 100% of the Registrable Securities and Convertible Securities held by a transferee or assignee of a Holder
to a non-Affiliate of such transferee or assignee, and (b) at least 2,000,000 shares (or such lesser number of shares as would be held by an Investor who has a Total Capital Commitment of $2,727,200 as defined in the Purchase Agreement, and who
has not sold any shares acquired under the Purchase Agreement) of the Convertible Securities or Registrable Securities (as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) to a
non-Affiliate; provided, however, that (i) the Company must receive notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect to which such
rights are being assigned, (ii) the Board of Directors must consent to the assignment, which consent shall not be unreasonably withheld, and (iii) such transferee or assignee must agree in writing to be bound by the terms and conditions of
this Agreement. Notwithstanding the limitation set forth in the foregoing sentence respecting the minimum number of shares which must be transferred, any Holder which is a corporation, partnership or limited liability company may transfer such
Holder’s Registration rights under Sections 3 and 4 to such Holder’s Affiliates, as the case may be, without restriction as to the number or percentage of shares acquired by any such Affiliates. 
  

 16 

 12. Market Standoff. Each Holder hereby agrees that, if so requested by the
Company and the Underwriter’s Representative (if any), such Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Registrable Securities or other securities of the
Company (“Market Standoff”) without the prior written consent of the Company and the Underwriter’s Representative for such period of time (a) not to exceed 180 days following the effective date of a Registration
Statement of the Company filed under the Securities Act in the case of the Initial Public Offering or (b) commencing with the date the Company provides notice to the Holders of a proposed follow-on offering pursuant to Section 4.1
(including Registrations initiated pursuant to Section 3) and ending 90 days after the effective date of the Registration Statement or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be
requested by the Underwriter’s Representative; provided, however, that a Holder shall not be required to agree to a Market Standoff for a period of time that commences less than 30 days after the expiration of another period of
time during which the Holder has agreed to a Market Standoff. The obligations of the Holders under this Section 12 shall be conditioned upon similar agreements being in effect with each other stockholder who is an officer, or director or, with
respect only to the Initial Public Offering, greater than 1% stockholder of the Company prior to such Initial Public Offering. 
 13.
Conversion of Preferred Stock. The Registration rights of the Holders of the Registrable Securities set forth in this Agreement are conditioned upon the conversion of the Registrable Securities with respect to which
registration is sought into Common Stock immediately prior to the closing of the offering of such Registrable Securities pursuant to an effective Registration Statement. 
 14. Reports Under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the
Commission that may at any time permit a Holder to sell securities of the Company to the public without Registration or pursuant to a registration on Form S-3, the Company agrees, for as long as a Holder holds Registrable Securities, to: 

(a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the
first Registration Statement filed by the Company for the offering of its securities to the public; 
 (b) take such action as is necessary
to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first Registration Statement filed by the Company for the offering
of its securities to the general public is declared effective; 
 (c) file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act; 
 (d) furnish to any Holder, so long as the Holder owns
any Registrable Securities, promptly upon request (i) a written statement by the Company that it has complied 

  

 17 

 
with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first Registration Statement filed by the Company),
the Securities Act, and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies),
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or
regulation of the Commission which permits the selling of any such securities without Registration or pursuant to such form; and 
 (e) at
any time, at the request of any Holder of Registrable Securities, make available to such Holder and to any prospective transferee of such Registrable Securities the information concerning the Company described in Rule 144A(d)(4) under the Securities
Act. 
 15. Miscellaneous. 
 15.1 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California excluding those laws that direct the application of the laws of another jurisdiction. 

15.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 15.3 Headings. The headings of the Sections of this Agreement
are for convenience and shall not by themselves determine the interpretation of this Agreement. 
 15.4 Notices. All notices
required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient,
or if not, then on the next business day; or (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall
be sent to the Company’s principal place of business. All notices to other parties to this Agreement shall be sent to the address as set forth on the signature page or at such other address as such party may designate by ten days advance notice
to the other parties. 
 15.5 Amendment and Waiver of Agreement. Except as otherwise provided herein, any provision of this
Agreement may be amended or waived only by a written instrument signed by the Company and Holders holding at least 60% of the Registrable Securities then held by all Holders. Notwithstanding the foregoing, neither Subsections 3.1(b) or 3.2(b), or
this sentence of Section 15.5, may be amended or waived without the consent of all Holders who have demand rights under Subsections 3.1(b) and 3.2(b). In addition, this Agreement may not be amended to increase any material financial
obligations of any Investor hereunder without the prior written consent of such Investor. Any waiver, amendment, modification or termination of any provision of this Agreement shall be binding on all parties hereto and their respective successors
and permitted assigns. 
  

 18 

 15.6 Severability. In the event one or more of the provisions of this Agreement should, for
any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained herein. 
 15.7 Entire Agreement; Successors and Assigns. This Agreement and
the Transactional Agreements (as defined below) constitute the entire agreement between the parties regarding the subject matter hereof and thereof and supersede and replace any and all prior negotiations, correspondence, understandings and
agreements, including without limitation the Prior Agreement, between the parties regarding the subject matter hereof and thereof. For purposes of this Agreement, the “Transactional Agreements” shall mean the Purchase
Agreement and the Second Amended and Restated Right of First Refusal and Co-Sale Agreement, each dated as of June 24, 2005, among the Company and other parties identified therein, the Second Amended and Restated Voting Agreement, dated as of
June 24, 2005, among the Company and the parties identified therein, and the Employment Agreements dated as of February 18, 2004 between the Company and each of the Executives named in Section 6.10 of the Purchase Agreement, each as
may be amended in accordance with its terms. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors, administrators,
heirs, successor, and permitted assigns of the parties. 
 15.8 Aggregation. All outstanding shares of capital stock of the
Company held or acquired by an Affiliate of a Person shall be aggregated together with all other shares of capital stock held by such Person for the purpose of determining the availability of any rights under this Agreement. 
 15.9 Cumulative Remedies. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other
right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not
prevent the concurrent assertion or employment of any other right or remedy. 
 15.10 Specific Performance. The parties hereto
hereby declare that it is impossible to measure in money the damages that will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree
that the terms of this Agreement shall be specifically enforceable. If any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom
such action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that
such remedy at law exists. 
 15.11 Accession; Amendment of Exhibit. Any person that becomes an Investor as defined in the
Purchase Agreement or a registered holder of a Series BB Warrant shall become a party to this Agreement by executing and delivering to the Company a counterpart signature pages to this Agreement and shall thereupon be deemed an “Investor”
for all purposes of this 

  

 19 

 
Agreement. The number of shares of Convertible Securities, Registrable Securities owned by each Investor, and the number of shares (if any) of Series BB
Preferred Stock subject to Series BB Warrants held by each Investor, as of the date hereof is set forth on Exhibit A, which exhibit may be amended from time to time by the Company upon notice to the Investors to reflect changes in the number
of shares of Convertible Securities or Registrable Securities owned by the Investors; provided, however, that no such notice shall be required upon the exercise of the Series BB Warrants by any of the Investors; provided further,
however, that the failure to so amend Exhibit A shall have no effect on the rights of the Investors under this Agreement. 
 [SIGNATURE
PAGES FOLLOW] 
  

 20 

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
  

			
	COMPANY:
	
	JAZZ PHARMACEUTICALS, INC.
		
	 Signature:
	 	 /s/ Carol A. Gamble

	 Print Name:
	 	 Carol A. Gamble

	 Title:
	 	 Sr. Vice President & General Counsel

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	KKR JP LLC
		
	Signature:	 	 /s/ Michael Michelson

	Print Name:	 	Michael Michelson
	Title:	 	  

	
	KKR JP III LLC
		
	Signature:	 	 /s/ Michael Michelson

	Print Name:	 	Michael Michelson
	Title:	 	  

	
	KKR TRS HOLDINGS, INC.
		
	Signature:	 	 /s/ Michael Michelson

	Print Name:	 	Michael Michelson
	Title:	 	  

  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	PROSPECT VENTURE PARTNERS II, L.P.
		
	 By:
	 	Prospect Management Co. II, LLC,
		 	its General Partner
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	PROSPECT ASSOCIATES II, L.P.
		
	 By:
	 	Prospect Management Co. II, LLC,
		 	its General Partner
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	VERSANT VENTURE CAPITAL II, L.P.
		
	By:	 	Versant Ventures II, L.L.C.,
		 	its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	VERSANT SIDE FUND II, L.P.
		
	By:	 	Versant Ventures II, L.L.C.,
		 	its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	VERSANT AFFILIATES FUND II-A, L.P.
		
	By:	 	Versant Ventures II, L.L.C.,
		 	its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	THOMA CRESSEY FUND VII, L.P.
		
	By:	 	TC Partners VII, L.P.
	Its:	 	General Partner
		
	By:	 	Thoma Cressey Bravo Inc.
	Its:	 	General Partner
		
	Signature:	 	 /s/ Bryan C. Cressey

	Print Name:	 	Bryan C. Cressey
	Title:	 	Managing Partner
	
	THOMA CRESSEY FRIENDS FUND VII, L.P.
		
	By:	 	TC Partners VII, L.P.
	Its:	 	General Partner
		
	By:	 	Thoma Cressey Bravo Inc.
	Its:	 	General Partner
		
	Signature:	 	 /s/ Bryan C. Cressey

	Print Name:	 	Bryan C. Cressey
	Title:	 	Managing Partner

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	JAZZ INVESTORS, L.L.C.
		
	By:	 	Beecken Petty & Company, L.L.C.,
		 	its Manager
		
	Signature:	 	 /s/ Kenneth W. O’Keefe

	Print Name:	 	Kenneth W. O’Keefe
	Title:	 	Partner

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 

			
	CCG INVESTMENT FUND, L.P.
		
	 By:
	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director
	
	CCG AV, LLC-SERIES C
		
	By:	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director
	
	CCG ASSOCIATES-QP, LLC
		
	By:	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director
	
	CCG INVESTMENT FUND-AI, LP
		
	By:	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director
	
	CCG CI, LLC
		
	By:	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director
	
	CCG AV, LLC — SERIES A
		
	By:	 	Golden Gate Capital Management, L.L.C.
	Its:	 	Authorized Representative
		
	By:	 	  

	Its:	 	Managing Director

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

							
	LB I GROUP INC.	 	LEHMAN BROTHERS HEALTHCARE VENTURE CAPITAL L.P.
				
	Signature:	 	 /s/ Alyson Goldfarb
	 	By:	 	Lehman Brothers HealthCare Venture Capital Associates
	Print Name:	 	Alyson Goldfarb	 		 	L.P., its General Partner
	Title:	 	Vice President	 		 	
		 		 	By:	 	LB I Group Inc., its General Partner
				
		 		 	Signature:	 	 /s/ Alyson Goldfarb

		 		 	Print Name:	 	Alyson Goldfarb
		 		 	Title:	 	Vice President
			
		 		 	LEHMAN BROTHERS P.A. LLC
				
		 		 	Signature:	 	 /s/ Deborah Nordell

		 		 	Print Name:	 	Deborah Nordell
		 		 	Title:	 	Vice President
			
		 		 	LEHMAN BROTHERS PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 		 	By:	 	LB I Group Inc., its General Partner
				
		 		 	Signature:	 	 /s/ Alyson Goldfarb

		 		 	Print Name:	 	Alyson Goldfarb
		 		 	Title:	 	Vice President
			
		 		 	LEHMAN BROTHERS OFFSHORE PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 		 	By:	 	Lehman Brothers Offshore Partners Ltd., its General Partner
				
		 		 	Signature:	 	 /s/ Alyson Goldfarb

		 		 	Print Name:	 	Alyson Goldfarb
		 		 	Title:	 	Vice President

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	BVCF IV, L.P.
		
	By:	 	Adams Street Partners, LLC, its General Partner
		
	Signature:	 	 /s/ Terry Gould

	Print Name:	 	Terry Gould
	Title:	 	Partner
	
	ADAMS STREET V, L.P.
		
	By:	 	Adams Street Partners, LLC, its General Partner
		
	Signature:	 	 /s/ Terry Gould

	Print Name:	 	Terry Gould
	Title:	 	Partner

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	EGS PRIVATE HEALTHCARE PARTNERSHIP II, L.P.
		
	By:	 	EGS Private Healthcare Investments, L.L.C., its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE INVESTORS II, L.P.
		
	By:	 	EGS Private Healthcare Investments, L.L.C., its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE CANADIAN PARTNERS, L.P.
		
	By:	 	EGS Private Healthcare Investments, L.L.C., its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE PRESIDENTS FUND, L.P.
		
	By:	 	EGS Private Healthcare Investments, L.L.C., its General Partner
		
	Signature:	 	  

	Print Name:	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	CARDINAL FUND I, L.P.
		
	By:	 	Cardinal Management I, L.P., General Partner
		
	By:	 	Cardinal MGP, L.L.C., General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	FW JAZZ PHARMA INVESTORS, L.P.
		
	By:	 	Group VI, 31, L.L.C., General Partner
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	WAUD CAPITAL PARTNERS, L.P.
		
	By:	 	Waud Capital Partners, L.L.C.
	Its:	 	General Partner
		
	Signature:	 	 /s/ Reeve B. Waud

	Print Name:	 	Reeve B. Waud
	Title:	 	Managing Member
	
	WAUD CAPITAL AFFILIATES, L.L.C.
		
	Signature:	 	 /s/ Reeve B. Waud

	Print Name:	 	Reeve B. Waud
	Title:	 	Managing Member
	
	DEEP COVE MEZZANINE, LLC
		
	Signature:	 	 /s/ Reeve B. Waud

	Print Name:	 	Reeve B.Waud
	Title:	 	Managing Member

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

									
	LERNER ENTERPRISES, L.P.	  		 	OAK HILL CREDIT ALPHA FINANCE I (OFFSHORE), LTD.
	By	  	 Oak Hill Advisors, L.P., as Investment Manager for Lerner Enterprises, L.P.
  
	  		 	Signature:	 	  

	Signature:	  	  
	  		 	Print Name:	 	  

	Print Name:	  	  
	  		 	Title:	 	  

	Title:	  	  
	  		 		 	
		  		  		 	OAK HILL CREDIT OPPORTUNITIES FINANCING, LTD.
					
		  		  		 	Signature:	 	  

		  		  		 	Print Name:	 	  

		  		  		 	Title:	 	  

				
		  		  		 	COAST DL FUNDING LLC
					
		  		  		 	Signature:	 	  

		  		  		 	Print Name:	 	  

		  		  		 	Title:	 	  

				
		  		  		 	OAK HILL CREDIT ALPHA FINANCE I, LLC
					
		  		  		 	By:	 	Oak Hill Credit Alpha Fund, L.P., its Member
					
		  		  		 	By:	 	Oak Hill Credit Alpha Gen Par, L.P.,
		  		  		 		 	its General Partner
					
		  		  		 	By:	 	Oak Hill Credit Alpha MGP, LLC.,
		  		  		 		 	its General Partner
					
		  		  		 	Signature:	 	  

		  		  		 	Print Name:	 	  

		  		  		 	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	GENERAL ELECTRIC PENSION TRUST
		
	By:	 	GE Asset Management Incorporated
		 	Its Investment Manager
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

	
	 /s/ Samuel R. Saks

	SAMUEL R. SAKS
	
	 /s/ Bruce C. Cozadd

	BRUCE C. COZADD
	
	 /s/ Robert M. Myers

	ROBERT M. MYERS
	
	 /s/ Janne L. T. Wissel

	JANNE L.T. WISSEL
	
	 /s/ Matthew K. Fust

	MATTHEW K. FUST
	
	 /s/ Carol A. Gamble

	CAROL A. GAMBLE

 Exhibit A 
 SCHEDULE OF INVESTORS 
  

			
	 Name and Address
	  	 Securities

	 KKR JP LLC
 9 W. 57th Street, 42nd Floor
 New York, NY 10019
	  	94,932,531 shares of Series B/P Preferred Stock
		
	 KKR JP III LLC
 9 W. 57th Street, 42nd Floor
 New York, NY 10019
	  	403,344 shares of Series B/P Preferred Stock
		
	 Thoma Cressey Fund VII, L.P.
 Sears Tower, 92nd Floor
 233 South Wacker Drive
 Chicago, IL 60606
	  	21,662,348 shares of Series B Preferred Stock
		
	 Thoma Cressey Friends Fund VII, L.P.
 Sears Tower,
92nd Floor
 233 South Wacker Drive
 Chicago, IL 60606
	  	338,237 shares of Series B Preferred Stock
		
	 CCG Investment Fund, LP
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor

San Francisco, CA 94111
	  	9,521,349 shares of Series B Preferred Stock
		
	 CCG AV, LLC-Series C
 c/o Golden Gate Capital

One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	480,987 shares of Series B Preferred Stock
		
	 CCG Associates-QP, LLC
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor

San Francisco, CA 94111
	  	523,132 shares of Series B Preferred Stock
		
	 CCG Investment Fund-AI, LP
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor

San Francisco, CA 94111
	  	127,553 shares of Series B Preferred Stock

			
	 Name and Address
	  	 Securities

	 CCG AV, LLC-Series A
 c/o Golden Gate Capital

One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	127,260 shares of Series B Preferred Stock
		
	 CCG CI, LLC
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	220,006 shares of Series B Preferred Stock
		
	 Jazz Investors, LLC
 c/o Beecken Petty & Company
Healthcare Equity Partners
 200 W. Madison Street, Suite 1910
 Chicago, IL 60606
	  	14,667,057 shares of Series B Preferred Stock
		
	 Lehman Brothers HealthCare Venture Capital L.P.
 399 Park
Avenue
 New York, NY 10022
 Attention: Fred
Steinberg
	  	1,833,382 shares of Series B Preferred Stock
		
	 Lehman Brothers P. A. L.L.C.
 399 Park Avenue

New York, NY 10022
 Attention: Fred Steinberg
	  	3,509,093 shares of Series B Preferred Stock
		
	 Lehman Brothers Partnership Account 2000/2001, L.P.
 399
Park Avenue
 New York, NY 10022
 Attention: Fred
Steinberg
	  	1,581,017 shares of Series B Preferred Stock
		
	 Lehman Brothers Offshore Partnership Account 2000/2001, L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred
Steinberg
	  	410,036 shares of Series B Preferred Stock
		
	 Prospect Venture Partners II, L.P.
 435 Tasso Street,
Suite 200
 Palo Alto, CA 94301
	  	 7,313,625 shares of Series A Preferred Stock
 6,139,997
shares of Series B Preferred Stock

			
	 Name and Address
	  	 Securities

	 Prospect Associates II, L.P.
 435 Tasso Street, Suite 200

 Palo Alto, CA 94301
	  	 111,375 shares of Series A Preferred Stock
 93,502 shares
of Series B Preferred Stock

		
	 Versant Venture Capital II, L.P.
 3000 Sand Hill Road

 Building 4, Suite 210
 Menlo Park, CA 94025
	  	 7,223,361 shares of Series A Preferred Stock
 6,064,216
shares of Series B Preferred Stock

		
	 Versant Side Fund II, L.P.
 3000 Sand Hill
Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	  	 64,559 shares of Series A Preferred Stock
 54,200 shares
of Series B Preferred Stock

		
	 Versant Affiliates Fund II-A, L.P.
 3000 Sand Hill Road

 Building 4, Suite 210
 Menlo Park, CA 94025
	  	 137,080 shares of Series A Preferred Stock
 115,083
shares of Series B Preferred Stock

		
	 BVCF IV, L.P.
 One North Wacker Drive, Suite
2200
 Chicago, IL 60606
	  	2,200,058 shares of Series B Preferred Stock
		
	 Adams Street V, L.P.
 One North Wacker Drive, Suite 2200

 Chicago, IL 60606
	  	2,200,058 shares of Series B Preferred Stock
		
	 Cardinal Fund I, L.P.
 201 Main Street, Suite
2415
 Fort Worth, TX 76102
 Attention: Ray Pinson
	  	 2,933,411 shares of Series B Preferred Stock
 Warrant to
Purchase 86,957 shares of Series BB Preferred Stock

		
	 FW Jazz Pharma Investors, L.P.
 201 Main Street, Suite
3100
 Fort Worth, TX 76102
 Attention: John H.
Fant
	  	 1,466,706 shares of Series B Preferred Stock
 Warrant to
Purchase 43,478 shares of Series BB Preferred Stock

		
	 EGS Private Healthcare Partnership II, L.P.
 105 Rowayton
Ave.
 Rowayton, CT 06853
	  	2,222,679 shares of Series B Preferred Stock

			
	 Name and Address
	  	 Securities

	 EGS Private Healthcare Investors II, L.P.
 105 Rowayton
Ave.
 Rowayton, CT 06853
	  	350,540 shares of Series B Preferred Stock
		
	 EGS Private Healthcare Canadian Partners, L.P.
 105
Rowayton Ave.
 Rowayton, CT 06853
	  	334,462 shares of Series B Preferred Stock
		
	 EGS Private Healthcare Presidents Fund, L.P.
 105
Rowayton Ave.
 Rowayton, CT 06853
	  	25,730 shares of Series B Preferred Stock
		
	 Samuel R. Saks
 2404 Hillside Drive
 Burlingame, CA 94010
	  	 2,640,000 shares of Common Stock
 150,000 shares of
Series A Preferred Stock
 733,352 shares of Series B Preferred Stock

		
	 Bruce C. Cozadd
 2316 Branner Dr.
 Menlo Park, CA 94025
	  	1,980,000 shares of Common Stock
733,352 shares of Series B Preferred Stock
		
	 Robert M. Myers
 1847 Hamilton Ave.
 Palo Alto, CA 94303
	  	 1,047,500 shares of Common Stock
 513,347 shares of
Series B Preferred Stock

		
	 Janne L.T. Wissel
 1514 Oriole Avenue
 Sunnyvale, CA 94087
	  	 330,000 shares of Common Stock
 733,352 shares of Series
B Preferred Stock

		
	 Matthew K. Fust
 1034 Noe St.
 San Francisco, CA 94114
	  	 330,000 shares of Common Stock
 220,005 shares of Series
B Preferred Stock

		
	 Carol A. Gamble
 625 Hurlingham Ave.
 San Mateo, CA 94402
	  	300,000 shares of Common Stock
		
	 Waud Capital Partners, L.P.
 560 Oakwood Avenue, Suite
203
 Lake Forest, IL 60045
	  	5,280,141 shares of Series B Preferred Stock

			
	 Name and Address
	  	 Securities

	 Waud Capital Affiliates, L.L.C.
 560 Oakwood Avenue,
Suite 203
 Lake Forest, IL 60045
	  	586,682 shares of Series B Preferred Stock
		
	 Deep Cove Mezzanine, LLC
 560 Oakwood Ave, Suite
203
 Lake Forest, IL 60045
	  	 Warrants to purchase 543,478 shares of Series BB
 Preferred Stock

		
	 Lerner Enterprises, LLP
 c/o Oak Hill Advisors
LP
 65 East 55th Street, 32nd Floor
 New York, NY
10022
	  	 Warrants to purchase 71,630 shares of Series BB
 Preferred Stock

		
	 LB I Group Inc.
 c/o Lehman Brothers
 399 Park Avenue, 9th Floor
 New York, NY 10022
	  	 Warrants to purchase 3,369,566 shares of Series BB
 Preferred Stock

		
	 KKR TRS Holdings, Inc.
 c/o KKR Financial
Corp.
 4 Embarcadero Center, Suite 2050
 San Francisco, CA 94111

	  	 Warrants to purchase 2,717,391 shares of Series BB
 Preferred Stock

		
	 General Electric Pension Trust
 c/o GE Asset Management
Incorporated
 3001 Summer Road
 P.O. Box 7900
 Stamford, CT 06904-7900
	  	 Warrants to purchase 869,565 shares of Series BB
 Preferred Stock

		
	 Coast DL Funding LLC
 c/o Oak Hill Advisors LP

65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	 Warrants to purchase 443,804 shares of Series BB
 Preferred Stock

		
	 Oak Hill Credit Opportunities Financing, Ltd.
 c/o Oak
Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY
10022
	  	 Warrants to purchase 294,348 shares of Series BB
 Preferred Stock

			
	 Name and Address
	  	 Securities

	 Oak Hill Credit Alpha Finance I
 (Offshore),
Ltd.
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor

 New York, NY 10022
	  	 Warrants to purchase 193,152 shares of Series BB
 Preferred Stock

		
	 Oak Hill Credit Alpha Finance I, LLC
 c/o Oak Hill
Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022

	  	 Warrants to purchase 62,283 shares of Series BB
 Preferred StockAmended Executive Change in Control and Severance Benefit Plan

 Exhibit 10.58 
 JAZZ PHARMACEUTICALS, INC. 
 EXECUTIVE
CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN 
 SECTION 1. INTRODUCTION. 
 The Jazz Pharmaceuticals, Inc. Executive Change in Control and Severance Benefit
Plan (the “Plan”) is hereby established effective May 1, 2007 (the “Effective Date”). The Plan was amended by the Board on July 18, 2007. The purpose of the Plan is to provide for the payment
of severance benefits to certain eligible executive employees of Jazz Pharmaceuticals, Inc. (the “Company”) or its Affiliates in the event that such employees are subject to qualifying employment
terminations in connection with a Change in Control. This Plan shall supersede any generally applicable severance or change in control plan, policy, or practice, whether written or unwritten, with respect to each employee who becomes a Participant
in the Plan. For the purposes of the foregoing sentence, a generally applicable severance or change in control plan, policy, or practice is a plan, policy, or practice in which benefits are not conditioned upon (i) being designated as a
participant, (ii) receiving an award such as a stock option, or (iii) the employee electing to participate. This Plan shall not supersede any individually negotiated employment contract or agreement, or any written plans that are not of
general application, and such Participant’s severance benefit, if any, shall be governed by the terms of such individually negotiated employment contract, agreement, or written plan, and shall be governed by this Plan only to the extent that
the reduction pursuant to Section 5(b) below does not entirely eliminate benefits under this Plan. This Plan document also constitutes the Summary Plan Description for the Plan. 
 SECTION 2. DEFINITIONS. 
 For purposes of the Plan, the following terms are defined as
follows: 
 (a) “Affiliate” means any “parent” or “subsidiary” of the Company as such terms
are defined in Rule 405 of the Securities Act of 1933, as amended. 
 (b) “Base
Salary” means the Participant’s annual base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation), at the rate in effect during the last regularly
scheduled payroll period immediately preceding the date of the Participant’s Covered Termination (without giving effect to any reduction in annual base pay after a Change in Control that would constitute grounds for Constructive Termination).

 (c) “Board” means the Board of Directors of Jazz Pharmaceuticals, Inc.

 (d) “Bonus Percentage” means the greater of any annual bonus, as a percentage
of annual base salary paid in the year of determination, paid to the Participant in respect of either of the last two calendar years prior to the date of a Covered Termination; provided, however, that if the Participant was not employed for
the entire calendar year prior to the date of a Covered Termination, the “Bonus Percentage” shall be the average bonus, as a percentage of annual base salary, for all similarly situated employees at the Company (e.g., all Vice
Presidents) who were employed for the entire calendar year prior to the date of a Covered Termination. 
  

 1. 

 (e) “Bonus Multiplier” means the quotient
obtained by dividing: (i) the sum of the number of full months that a Participant is employed in the year of a Covered Termination and twelve (12), by (ii) twelve (12). 
 (f) “Cause” means the occurrence of any one or more of the following: (i) the
Participant’s unauthorized use or disclosure of the confidential information or trade secrets of Company or its Affiliates which use or disclosure causes material harm to the Company or an Affiliate; (ii) the Participant’s material
breach of any agreement between the Participant and the Company or an Affiliate which remains uncured for ten (10) days after receiving written notification of the breach from the Board; (iii) the Participant’s material failure to
comply with the written policies or rules of the Company or an Affiliate which remains uncured for ten (10) days after receiving written notification of the breach from the Board; (iv) the Participant’s conviction of, or plea of
“guilty” or “no contest” to, any crime involving fraud, dishonesty, or moral turpitude under the laws of any United States Federal, state, local, or foreign governmental authority; (v) the Participant’s gross
misconduct; (vi) the Participant’s continuing failure to perform assigned duties after receiving written notification of the failure from the Board; or (vii) the Participant’s failure to cooperate in good faith with a
governmental or internal investigation of the Company, its Affiliates, directors, officers, or employees, if the Board has requested the Participant’s cooperation. 
 (g) “Change in Control” shall mean the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

 (i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than fifty
percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur
(A) on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions
that are primarily a private financing transaction for the Company or (B) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated
percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the
operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other
acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; 
 (ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company if, immediately after the
consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent
(50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the 

  

 2. 

 
combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in either case, in
substantially the same proportions as their ownership of the voting power of the Company’s securities immediately prior to such merger, consolidation or similar transaction; 
 (iii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete
dissolution or liquidation of the Company shall otherwise occur; or 
 (iv) there is consummated a sale, lease, license or other
disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries
to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportion as their Ownership of the Company immediately prior to such
sale, lease, license or other disposition. 
 The term Change in Control shall not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company. 
 (h)
“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 
 (i) “Code” means the Internal Revenue Code of 1986, as amended. 
 (j)
“Company” means Jazz Pharmaceuticals, Inc. or, following a Change in Control which is a sale of assets or a merger in which Jazz Pharmaceuticals, Inc. is not the surviving entity, the entity to
which the assets are sold or the surviving entity resulting from such transaction, respectively. 
 (k)
“Constructive Termination” means a resignation of employment by a Participant after an action or event which constitutes Good Reason is undertaken by the Company or an Affiliate, or occurs.

 (l) “Covered Termination” means either (i) an Involuntary Termination
Without Cause, or (ii) a Constructive Termination, in each case within twelve (12) months following a Change in Control. Termination of employment of a Participant due to death or disability shall not constitute a Covered Termination
unless a resignation of employment by the Participant immediately prior to the Participant’s death or disability would have qualified as a Constructive Termination. 
 (m) “Entity” means a corporation, partnership, limited liability company, or other entity. 
 (n) “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 
 (o) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  

 3. 

 (p) “Exchange Act Person” means any natural
person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (A) the Company or any Subsidiary of the Company; (B) any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company; (C) an underwriter temporarily holding securities
pursuant to an offering of such securities; or (D) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company. 
 (q) “Involuntary Termination Without Cause” means a termination by the Company of a
Participant’s employment relationship with the Company or an Affiliate for any reason other than for Cause. 
 (r)
“Good Reason” means the occurrence of any one or more of the following actions or events: (i) a reduction in the Participant’s Base Salary by more than ten percent (10%) (other
than a reduction in conjunction with (x) a Company-wide salary reduction, or (y) a salary reduction involving senior management of the Company which results in salary reductions for employees similarly-situated to the Participant);
(ii) a relocation of Participant’s place of employment by more than thirty-five (35) miles; provided and only if such reduction or relocation is effected without the Participant’s consent; (iii) a substantial reduction in
the Participant’s duties or responsibilities (and not simply a change in reporting relationships) in effect prior to the effective date of the Change in Control; provided, however, that it shall not constitute “Good Reason” if,
following the effective date of the Change in Control, either (x) the Company is retained as a separate legal entity or business unit and the Participant holds the same position in such legal entity or business unit as the Participant held
before such effective date, or (y) the Participant holds a position with duties and responsibilities comparable (though not necessarily identical, in view of the relative sizes of the Company and the entity involved in the Change in Control) to
the duties and responsibilities of the Participant prior to the effective date of the Change in Control; (iv) a reduction in the Participant’s title (e.g., the Participant no longer has a “Vice President” title); or
(v) required travel by the Participant on the Company’s business is substantially increased compared with the Participant’s business travel obligations prior to the Change in Control, provided and only if such increased business
travel is effected without the Participant’s consent. 
 (s) “Own,” “Owned,”
“Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity,
directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 
 (t) “Participant” means an individual who has been designated a Participant by the Plan
Administrator in its sole discretion (either by a specific designation or by virtue of being a member of a class of employees who have been so designated). 
 (u) “Plan Administrator” means the Board or any committee duly authorized by the Board to administer the Plan. The Plan Administrator may, but is not required
to be, the Compensation Committee of the Board. The Board may at any time administer the Plan, in whole or in part, notwithstanding that the Board has previously appointed a committee to act as the Plan Administrator. 
  

 4. 

 (v) “Subsidiary” shall mean any corporation (other than the Company) in an
unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date. 
 SECTION 3. ELIGIBILITY FOR BENEFITS. 
 (a) General Rules. Subject to the limitations set forth in this Section 3 and Section 5, in the event of a Covered Termination, the Company shall provide the severance benefits described in
Section 4 to each affected Participant. 
 (b) Exceptions to Benefit Entitlement. A Participant will not receive benefits under
the Plan (or will receive reduced benefits under the Plan) in the following circumstances, as determined by the Plan Administrator in its sole discretion: 
 (i) The Participant has executed an individually negotiated employment contract or agreement with the Company relating to severance or change in control benefits that is in effect on his or her termination date
and which provides benefits that the Plan Administrator, in its sole discretion, determines to be of greater value than the benefits provided for in this Plan, in which case such Participant’s severance benefit, if any, shall be governed by the
terms of such individually negotiated employment contract or agreement and shall be governed by this Plan only to the extent that the reduction pursuant to Section 5(b) below does not entirely eliminate benefits under this Plan. 
 (ii) The Participant is entitled to receive benefits under another severance benefit plan maintained by the Company on his or her termination date
and which provides benefits that the Plan Administrator, in its sole discretion, determines to be of greater value than the benefits provided for in this Plan, in which case such Participant’s severance benefit, if any, shall be governed by the
terms of such other severance benefit plan and shall be governed by this Plan only to the extent that the reduction pursuant to Section 5(b) below does not entirely eliminate benefits under this Plan. 
 (iii) The Participant’s employment terminates or is terminated for any reason other than a Covered Termination. 
 (iv) The Participant voluntarily terminates employment with the Company in order to accept employment with another entity that is controlled
(directly or indirectly) by the Company or is otherwise an Affiliate. 
 (v) The Participant does not confirm in writing that he or
she shall be subject to the Company’s Employee Confidential Information and Inventions Agreement. 
  

 5. 

 (vi) The Participant is rehired prior to the date benefits under the Plan are scheduled to
commence by the Company or an Affiliate for an identical or substantially equivalent or comparable position as the Participant’s last position with the Company or an Affiliate. 
 (vii) The Participant is offered an identical or substantially equivalent or comparable position with the Company, an Affiliate, or a successor
pursuant to a Change in Control. For purposes of the foregoing, a “substantially equivalent or comparable position” is one that offers the Participant substantially the same level of responsibility and Base Salary; provided,
however, that a Participant shall not be considered to be offered a “substantially equivalent or comparable position” if a resignation by the Participant would constitute Constructive Termination. 
 (viii) The Participant has failed to execute or has revoked the release described in Section 5(a). 
 (c) Termination of Benefits. A Participant’s right to receive benefits under this Plan shall terminate immediately if, at any time prior to
or during the period for which the Participant is receiving benefits hereunder, the Participant, without the prior written approval of the Plan Administrator: 
 (i) willfully breaches a material provision of the Company’s Employee Confidential Information and Inventions Agreement; 
 (ii) encourages or solicits any of the Company’s then current employees to leave the Company’s employ for any reason or interferes in
any other manner with employment relationships at the time existing between the Company and its then current employees; or 
 (iii)
induces any of the Company’s then current clients, customers, suppliers, vendors, distributors, licensors, licensees or other third party to terminate their existing business relationship with the Company or interferes in any other manner
with any existing business relationship between the Company and any then current client, customer, supplier, vendor, distributor, licensor, licensee or other third party. 
 SECTION 4. AMOUNT OF BENEFITS. 
 In the event of a
Participant’s Covered Termination, the Participant shall be entitled to receive the benefits provided by this Section 4. 
 (a)
Cash Severance Benefits. The Company shall make a cash severance payment to the Participant in an amount equal to the sum of (i) the Participant’s Base Salary, and (ii) the product of (A) the Participant’s Base Salary,
and (B) the Participant’s Bonus Percentage, and (C) the Participant’s Bonus Multiplier. Such severance payment shall be paid in accordance with Section 6. 
  

 6. 

 (b) Health Continuation Coverage. 
 (i) Provided that the Participant is eligible for, and has made an election at the time of the Covered Termination pursuant to COBRA under a
health, dental, or vision plan sponsored by the Company, each such Participant shall be entitled to payment by the Company of all of the applicable premiums (inclusive of premiums for the Participant’s dependents for such health, dental, or
vision plan coverage as in effect immediately prior to the date of the Covered Termination) for such health, dental, or vision plan coverage for a period of twelve (12) months following the date of the Covered Termination, with such coverage
counted as coverage pursuant to COBRA. 
 (ii) No such premium payments (or any other payments for health, dental, or vision coverage
by the Company) shall be made following the Participant’s death or the effective date of the Participant’s coverage by a health, dental, or vision insurance plan of a subsequent employer. Each Participant shall be required to notify the
Plan Administrator immediately if the Participant becomes covered by a health, dental, or vision insurance plan of a subsequent employer. Upon the conclusion of such period of insurance premium payments made by the Company, the Participant will be
responsible for the entire payment of premiums required under COBRA for the duration of the COBRA period. 
 (iii) For purposes of
this Section 4(b), (i) references to COBRA shall be deemed to refer also to analogous provisions of state law, and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by the
Participant under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are the sole responsibility of the Participant. 
 (c) Stock Award Vesting Acceleration. Upon a Covered Termination, (i) the vesting and exercisability of all outstanding options to purchase the Company’s common stock (or stock appreciation
rights or similar rights or other rights with respect to stock of the Company issued pursuant to any equity incentive plan of the Company) that are held by the Participant on such date shall be accelerated in full, and (ii) any reacquisition or
repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to similar rights or other rights with respect to stock of the Company issued or issuable pursuant to any equity incentive plan of the Company)
pursuant to any other stock award granted to the Participant by the Company shall lapse. 
 (d) Other Employee Benefits. All other
benefits (such as life insurance, disability coverage, and 401(k) plan coverage) shall terminate as of the Participant’s termination date (except to the extent that a conversion privilege may be available thereunder). 
 (e) Additional Benefits. Notwithstanding the foregoing, the Plan Administrator may, in its sole discretion, provide benefits in addition to those
pursuant to Sections 4(a), 4(b), and 4(c) to one or more Participants chosen by the Plan Administrator, in its sole discretion, and the provision of any such benefits to a Participant shall in no way obligate the Company to provide such benefits to
any other Participant, even if similarly situated. 
  

 7. 

 SECTION 5. LIMITATIONS ON BENEFITS. 
 (a) Release. In order to be eligible to receive benefits under the Plan, a Participant must execute a general waiver and release in substantially
the form attached hereto as EXHIBIT A, EXHIBIT B, or EXHIBIT C, as appropriate, and such release must become effective in accordance with its terms; provided, however, no such
release shall require the Participant to forego any unpaid salary, any accrued but unpaid vacation pay or any benefits payable pursuant to this Plan. With respect to any outstanding option held by the Participant, no provision set forth in this Plan
granting the Participant additional rights to exercise the option can be exercised unless and until the release becomes effective. Unless a Change in Control has occurred, the Plan Administrator, in its sole discretion, may modify the form of the
required release to comply with applicable law and shall determine the form of the required release, which may be incorporated into a termination agreement or other agreement with the Participant. 
 (b) Certain Reductions. The Plan Administrator, in its sole discretion, shall have the authority to reduce a Participant’s severance
benefits, in whole or in part, by any other severance benefits, pay in lieu of notice, or other similar benefits payable to the Participant by the Company that become payable in connection with the Participant’s termination of employment
pursuant to (i) any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act (the “WARN Act”), (ii) a written employment or
severance agreement with the Company, or (iii) any Company policy or practice providing for the Participant to remain on the payroll for a limited period of time after being given notice of the termination of the Participant’s employment.
The benefits provided under this Plan are intended to satisfy, in whole or in part, any and all statutory obligations and other contractual obligations of the Company, including benefits provided by offer letter or employment agreements, that may
arise out of a Participant’s termination of employment, and the Plan Administrator shall so construe and implement the terms of the Plan. The Plan Administrator’s decision to apply such reductions to the severance benefits of one
Participant and the amount of such reductions shall in no way obligate the Plan Administrator to apply the same reductions in the same amounts to the severance benefits of any other Participant, even if similarly situated. In the Plan
Administrator’s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments pursuant to the Company’s statutory or other contractual obligations.

 (c) Parachute Payments. Except as otherwise provided in an agreement between a Participant and the Company, if any payment or
benefit the Participant would receive in connection with a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning
of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to
the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the
total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s
receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is

  

 8. 

 
necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless the Participant elects in writing a different
order (provided, however, that such election shall be subject to Company approval if made on or after the date on which the event that triggers the Payment occurs): (1) reduction of cash payments; (2) cancellation of accelerated
vesting of equity awards other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to a Participant. If acceleration of vesting of compensation from a Participant’s
equity awards is to be reduced, such acceleration of vesting shall be cancelled by first canceling such acceleration for the vesting installment that will vest last and continuing by canceling as a first priority such acceleration for vesting
installments with the latest vesting unless the Participant elects in writing a different order for cancellation prior to any Change in Control. 
 (d) Mitigation. Except as otherwise specifically provided herein, a Participant shall not be required to mitigate damages or the amount of any payment provided under this Plan by seeking other employment or otherwise, nor shall the
amount of any payment provided for under this Plan be reduced by any compensation earned by a Participant as a result of employment by another employer or any retirement benefits received by such Participant after the date of the Participant’s
termination of employment with the Company, except for health continuation coverage provided pursuant to Section 4(b). 
 (e)
Non-Duplication of Benefits. Except as otherwise specifically provided for herein, no Participant is eligible to receive benefits under this Plan or pursuant to other contractual obligations more than one time. This Plan is designed to provide
certain severance pay and change in control benefits to Participants pursuant to the terms and conditions set forth in this Plan. The payments pursuant to this Plan are in addition to, and not in lieu of, any unpaid salary, bonuses or benefits to
which a Participant may be entitled for the period ending with the Participant’s Covered Termination. 
 SECTION 6. TIME
OF PAYMENT AND FORM OF BENEFITS. 
 (a)
General Rules. Except as otherwise set forth in the Plan, the cash severance benefits under Section 4(a) of the Plan, if any, shall be paid in a single lump sum payment on the first payroll date following the Participant’s
Covered Termination. In no event shall payment of any Plan benefit set forth in Section 4 be made prior to the effective date of the release described in Section 5(a). For the avoidance of doubt, in the event of an acceleration of the
exercisability of an option (or other award) pursuant to Section 4(c), such option (or other award) shall not be exercisable with respect to such acceleration of exercisability unless and until the effective date of the release described in
Section 5(a). 
 (b) Application of Section 409A. 
 (i) To the extent that the sum of (i) any cash severance benefit provided under Section 4(a), and (ii) any additional benefits
provided under Section 4(e) (collectively, the “Payments”) does not exceed the lesser of: (x) two (2) times the sum of the Participant’s annualized compensation based upon the
annual rate of pay for services provided to the Company (or an Affiliate or a successor entity, if applicable) for the taxable year of the Participant preceding the taxable year of the Participant in which the Participant incurs a 

  

 9. 

 
Covered Termination (adjusted for any increase during such latter year that was expected to continue indefinitely if the Participant had not incurred a
Covered Termination), or (y) two (2) times the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which the Participant incurs a Covered Termination (the
“Permitted Window Program Payments”), such Permitted Window Program Payments shall be paid pursuant to Section 6(a); provided, however, such portion of the Payments, to the extent of
the Permitted Window Program Payments, shall in no event be paid later than the last day of the second taxable year of the Participant following the taxable year of the Participant in which occurs the Covered Termination. The Permitted Window
Program Payments are intended to constitute separate payments for purposes of Treas. Reg. Section 1.409A-2(b)(2) that are payable pursuant to a “window program” to the maximum extent permitted by Treas. Reg.
Section 1.409A-1(b)(9)(iii). 
 (ii) If a Participant is a “specified employee” of the Company or its Affiliates (or
any successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of a Covered Termination, then the Payments, to the extent in excess of the Permitted Window Program Payments, shall be delayed until the
earlier of: (i) the date that is six (6) months after the date of the Covered Termination, or (ii) the date of Participant’s death (such date, the “Delayed Initial Payment
Date”), and the Company (or the successor entity thereto, as applicable) shall pay to the Participant a lump sum amount equal to the sum of the Payments that the Participant would otherwise have received on or before the
Delayed Initial Payment Date, without any adjustment on account of such delay, if the Payments had not been delayed pursuant to this Section 6(b)(ii), and (B) pay the balance of the Payments in accordance with any applicable payment
schedules set forth herein. Payments pursuant to this Section 6(b)(ii) are intended to constitute separate payments for purposes of Treas. Reg. Section 1.409A-2(b)(2). 
 (iii) If a Participant is not a “specified employee” of the Company or its Affiliates (or any successor entity thereto) within the
meaning of Section 409A(a)(2)(B)(i) of the Code on the date of a Covered Termination, then the Payments, to the extent in excess of the Permitted Window Program Payments, shall be paid pursuant to Section 6(a). 
 (c) Tax Withholding. All payments under the Plan will be subject to all applicable withholding of the Company, including, without
limitation, obligations to withhold for federal, state and local income and employment taxes. 
 (d) Indebtedness of Participants. If
a Participant is indebted to the Company on the effective date of his or her Covered Termination, the Plan Administrator reserves the right to offset any severance payments under the Plan by the amount of such indebtedness. 
 SECTION 7. RIGHT TO INTERPRET PLAN; AMENDMENT AND
TERMINATION. 
 (a) Exclusive Discretion. The Plan Administrator shall have the exclusive discretion and authority
to establish rules, forms, and procedures for the administration of the Plan, and to construe and interpret the Plan and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with
the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid under the Plan. The rules, interpretations, computations and other actions of the Plan Administrator shall be binding
and conclusive on all persons. 
  

 10. 

 (b) Amendment or Termination. The Company reserves the right to amend or terminate this Plan, or
the benefits provided hereunder at any time; provided, however, that no such amendment or termination shall occur following a Change in Control or a Covered Termination as to any Participant who would be adversely affected by such amendment
or termination unless such Participant consents in writing to such amendment or termination. Any action amending or terminating the Plan shall be in writing and executed by a duly authorized officer of the Company. 
 SECTION 8. NO IMPLIED EMPLOYMENT CONTRACT. 
 The Plan shall not be deemed (i) to give any employee or other person any right to be retained in the employ of the Company or an Affiliate, or
(ii) to interfere with the right of the Company or an Affiliate to discharge any employee or other person at any time, with or without cause, which right is hereby reserved. 
 SECTION 9. LEGAL CONSTRUCTION. 
 This Plan is intended to be governed by
and shall be construed in accordance with ERISA and, to the extent not preempted by ERISA, the laws of the State of California. 
 SECTION 10.
CLAIMS, INQUIRIES AND APPEALS. 
 (a) Applications for Benefits and
Inquiries. Any application for benefits, inquiries about the Plan or inquiries about present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or her authorized representative). The
Plan Administrator is set forth in Section 12(d). 
 (b) Denial of Claims. In the event that any application for benefits
is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s right to review the denial. Any electronic notice will comply with the
regulations of the U.S. Department of Labor. The notice of denial will be set forth in a manner designed to be understood by the applicant and will include the following: 
 (i) the specific reason or reasons for the denial; 
 (ii) references to the specific Plan
provisions upon which the denial is based; 
 (iii) a description of any additional information or material that the Plan
Administrator needs to complete the review and an explanation of why such information or material is necessary; and 
 (iv) an
explanation of the Plan’s review procedures and the time limits applicable to such procedures, including a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of the
claim, as described in Section 10(d) below. 
  

 11. 

 This notice of denial will be given to the applicant within ninety (90) days after the Plan
Administrator receives the application, unless special circumstances require an extension of time, in which case, the Plan Administrator has up to an additional ninety (90) days for processing the application. If an extension of time for
processing is required, written notice of the extension will be furnished to the applicant before the end of the initial ninety (90) day period. 
 This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the application. 
 (c) Request for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied, in whole or
in part, may appeal the denial by submitting a request for a review to the Plan Administrator within sixty (60) days after the application is denied. A request for a review shall be in writing and shall be addressed to: 
 Jazz Pharmaceuticals, Inc. 
 Attn: General
Counsel 
 3180 Porter Drive 
 Palo
Alto, CA 94304 
 A request for review must set forth all of the grounds on which it is based, all facts in support of the request and any
other matters that the applicant feels are pertinent. The applicant (or his or her representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other
information relating to his or her claim. The applicant (or his or her representative) shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his or her
claim. The review shall take into account all comments, documents, records and other information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information was submitted or considered
in the initial benefit determination. 
 (d) Decision on Review. The Plan Administrator will act on each request for review within
sixty (60) days after receipt of the request, unless special circumstances require an extension of time (not to exceed an additional sixty (60) days), for processing the request for a review. If an extension for review is required, written
notice of the extension will be furnished to the applicant within the initial sixty (60) day period. This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator
is to render its decision on the review. The Plan Administrator will give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor. In the event
that the Plan Administrator confirms the denial of the application for benefits in whole or in part, the notice will set forth, in a manner calculated to be understood by the applicant, the following: 
 (i) the specific reason or reasons for the denial; 
  

 12. 

 (ii) references to the specific Plan provisions upon which the denial is based; 
 (iii) a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents,
records and other information relevant to his or her claim; and 
 (iv) a statement of the applicant’s right to bring a civil
action under Section 502(a) of ERISA. 
 (e) Rules and Procedures. The Plan Administrator will establish rules and procedures,
consistent with the Plan and with ERISA, as necessary and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant who wishes to submit additional information in connection with an
appeal from the denial of benefits to do so at the applicant’s own expense. 
 (f) Exhaustion of Remedies. No legal action for
benefits under the Plan may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 10(a) above, (ii) has been notified by the Plan Administrator that
the application is denied, (iii) has filed a written request for a review of the application in accordance with the appeal procedure described in Section 10(c) above, and (iv) has been notified that the Plan Administrator has denied
the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an applicant’s claim or appeal within the relevant time limits specified in this Section 10, the applicant may bring legal action for benefits under
the Plan pursuant to Section 502(a) of ERISA. 
 SECTION 11. BASIS OF PAYMENTS TO
AND FROM PLAN. 
 The Plan shall be unfunded, and all benefits hereunder shall be paid only
from the general assets of the Company. 
 SECTION 12. OTHER PLAN INFORMATION. 
 (a) Employer and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan Sponsor” as
that term is used in ERISA) by the Internal Revenue Service is 05-0563787. The Plan Number assigned to the Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 510. 
 (b) Ending Date for Plan’s Fiscal Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s records is
December 31. 
 (c) Agent for the Service of Legal Process. The agent for the service of legal process with respect to the Plan
is: 
 Jazz Pharmaceuticals, Inc. 
 Attn: General Counsel 
 3180 Porter Drive 
 Palo Alto, CA 94304 
  

 13. 

 (d) Plan Sponsor and Administrator. The “Plan Sponsor” of the Plan is: 
 Jazz Pharmaceuticals, Inc. 
 Attn: General
Counsel 
 3180 Porter Drive 
 Palo
Alto, CA 94304 
 The “Plan Administrator” of the Plan is as set forth in Section 2(u). The Plan Sponsor’s and Plan Administrator’s
telephone number is (650) 496-3777 The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan. 
 SECTION 13. STATEMENT OF ERISA RIGHTS. 
 Participants in this Plan (which is a
welfare benefit plan sponsored by Jazz Pharmaceuticals, Inc.) are entitled to certain rights and protections under ERISA. If you are a Participant, you are considered a participant in the Plan for the purposes of this Section 13 and, under
ERISA, you are entitled to: 
 (a) Receive Information About Your Plan and Benefits 
 (i) Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents governing
the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration; 
 (ii) Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest
annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Plan Administrator may make a reasonable charge for the copies; and 
 (iii) Receive a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is required by law to furnish each
participant with a copy of this summary annual report. 
 (b) Prudent Actions By Plan Fiduciaries. In addition to creating rights for
Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the
interest of you and other Plan participants and beneficiaries. No one, including your employer, your union or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a Plan benefit or exercising
your rights under ERISA. 
 (c) Enforce Your Rights. 
 (i) If your claim for a Plan benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal
any denial, all within certain time schedules. 
  

 14. 

 (ii) Under ERISA, there are steps you can take to enforce the above rights. For instance, if you
request a copy of Plan documents or the latest annual report from the Plan, if applicable, and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the
materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 
 (iii) If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court. 

(iv) If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file
suit in a Federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and
fees, for example, if it finds your claim is frivolous. 
 (d) Assistance With Your Questions. If you have any questions about the
Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of
the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution
Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 
 SECTION 14. GENERAL PROVISIONS. 
 (a) Notices. Any notice, demand or request required or permitted to be given by either the Company or a Participant pursuant to the terms of this Plan shall be in writing and shall be deemed given when delivered personally or
deposited in the U.S. mail, First Class with postage prepaid, and addressed to the parties, in the case of the Company, at the address set forth in Section 12(d) and, in the case of a Participant, at the address as set forth in the
Company’s employment file maintained for the Participant as previously furnished by the Participant or such other address as a party may request by notifying the other in writing. 
 (b) Transfer and Assignment. The rights and obligations of a Participant under this Plan may not be transferred or assigned without the prior
written consent of the Company. This Plan shall be binding upon any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried
on by the Company without regard to whether or not such person or entity actively assumes the obligations hereunder. 
 (c) Waiver.
Any Party’s failure to enforce any provision or provisions of this Plan shall not in any way be construed as a waiver of any such provision or provisions, nor prevent any Party from thereafter enforcing each and every other provision of
this Plan. The rights granted the Parties herein are cumulative and shall not constitute a waiver of any Party’s right to assert all other legal remedies available to it under the circumstances. 
  

 15. 

 (d) Severability. Should any provision of this Plan be declared or determined to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired. 
 (e) Section Headings. Section headings in this Plan are included for convenience of reference only and shall not be considered part of this Plan for any other purpose. 
 SECTION 15. EXECUTION. 
 To record the
adoption of the Plan as set forth herein, Jazz Pharmaceuticals, Inc. has caused its duly authorized officer to execute the same as of the Effective Date. 
  

			
	JAZZ PHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Carol A. Gamble

	 Title:
	 	Sr. Vice President & General Counsel

  

 16. 

 For Employees Age 40 or Older 
 Individual Termination 
  

 EXHIBIT A 
 RELEASE AGREEMENT (“RELEASE”) 
 I understand and agree
completely to the terms set forth in the Jazz Pharmaceuticals, Inc. Executive Change in Control Severance Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not
relying on any promise or representation by the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee Confidential Information and Inventions Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and
have not suffered any on-the-job injury for which I have not already filed a claim. 
 In exchange for the consideration provided to me by this Release that
I am not otherwise entitled to receive, I hereby generally and completely release Jazz Pharmaceuticals, Inc. and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and
subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing
this Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or
benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of
contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all
federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities
Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this
Release by filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and
agree that I shall not recover any monetary benefits in connection with any challenge to my Release. 
 I acknowledge that I am knowingly and voluntarily
waiving and releasing any rights I may have under the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the 

  

 A-1 

 For Employees Age 40 or Older 
 Individual Termination 
  

 
ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required
by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have twenty-one (21) days to
consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be effective until the date upon
which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 
 I acknowledge that I have read and understand
Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known
by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my
release of any claims hereunder. 
 I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not
later than twenty-one (21) days following the date it is provided to me. 
  

			
	EXECUTIVE
		
	 Name:
	 	  

	 Date:
	 	  

  

 A-2 

 For Employees Age 40 or Older 
 Group Termination 
  

 EXHIBIT B 
 RELEASE AGREEMENT (“RELEASE”) 
 I understand and agree
completely to the terms set forth in the Jazz Pharmaceuticals, Inc. Executive Change in Control Severance Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not
relying on any promise or representation by the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee Confidential Information and Inventions Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and
have not suffered any on-the-job injury for which I have not already filed a claim. 
 Except as otherwise set forth in this Release, I hereby generally and
completely release Jazz Pharmaceuticals, Inc. and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any
and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to:
(a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of
1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any
proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in
connection with any challenge to my Release. 
 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA
(“ADEA Waiver”). I also acknowledge that the consideration given for the 

  

 B-1 

 For Employees Age 40 or Older 
 Group Termination 
  

 
ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required
by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have forty-five (45) days to
consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and (e) the ADEA Waiver will not be effective until the date upon
which the revocation period has expired unexercised, which will be the eighth day after I sign this Release.
 I have received with this Release a written
disclosure of all of the information required by the ADEA, including without limitation a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the
same job classification or organizational unit who were not terminated, along with information on the eligibility factors used to select employees for the group termination and any time limits applicable to this group termination program.

 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not
extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby
expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 
 I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than forty-five (45) days following the date this Release and the ADEA disclosure form
is provided to me. 
  

			
	EXECUTIVE
		
	 Name:
	 	  

	 Date:
	 	  

  

 B-2 

 For Employees Under Age 40 
 Individual and Group Termination 
  

 EXHIBIT C 
 RELEASE AGREEMENT (“RELEASE”) 
 I understand and agree
completely to the terms set forth in the Jazz Pharmaceuticals, Inc. Executive Change in Control Severance Benefit Plan (the “Plan”). 
 I understand that this Release, together with the Plan, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not
relying on any promise or representation by the Company that is not expressly stated therein. Certain capitalized terms used in this Release are defined in the Plan. 
 I hereby confirm my obligations under my Employee Confidential Information and Inventions Agreement with the Company. 
 I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and
have not suffered any on-the-job injury for which I have not already filed a claim. 
 In exchange for the consideration provided to me by this Release that
I am not otherwise entitled to receive, I hereby generally and completely release Jazz Pharmaceuticals, Inc. and its current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and
subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing
this Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or
benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of
contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all
federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities
Act of 1990, and the California Fair Employment and Housing Act (as amended). Nothing in this Release shall prevent me from challenging this Release by filing, cooperating with, or participating in any proceeding before the Equal Employment
Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in connection with any challenge to my Release.

 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release
does not extend to claims which the creditor does not 

  

 C-1 

 For Employees Under Age 40 
 Individual and Group Termination 
  

 
know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her
settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 
 I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than fourteen (14) days following the
date it is provided to me. 
  

			
	EXECUTIVE
		
	 Name:
	 	  

	 Date:
	 	  

  

 C-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]